510(k) device
Tbd
Lensar, Inc. · Ophthalmic Femtosecond Laser (OOE, Class II) · First FDA decision Oct 19, 2011, newest Mar 27, 2013Cataract
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
3
510(k) pathway
Device trials
4
Naming "Tbd"
MAUDE reports
427
Brand "Tbd", since 2015
PubMed studies
1,048
Mentioning "Tbd"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Tbd
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 3 of 3 decisions filed under this name.
- TBD510(k)
K123859 · Decided Mar 27, 2013 · 103 days after receipt
Device type: Ophthalmic Femtosecond Laser (OOE) · Ophthalmology
2 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Tbd", any status and sponsor, newest update first.
Masonic Cancer Center, University of MinnesotaAcademic, hospital or other
NCT03579875 · 48 participants (planned) · Start Nov 13, 2018 · Primary completion Jan 1, 2027
Device: Donor mobilized PBSC infusion · For: Fanconi Anemia; Severe Aplastic Anemia; Myelodysplastic Syndromes and 5 more
Sites: Minneapolis, Minnesota
3 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Tbd", and for the whole product code for context.
This brand
427 reports: 356 malfunction, 70 injury, 1 death
Whole product code OOE
4,559 reports: 2,002 malfunction, 2,527 injury, 0 death
Newest reports for this brand
- TBDMalfunction
MEDTRONIC PUERTO RICO OPERATIONS CO., HU
2647346-2026-00494 · Received Sep 10, 2026 · Event dated Aug 18, 2026
Device type: Drills, Burrs, Trephines & Accessories (Simple, Powered) (HBE)
Device problem as coded: Fracture
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
4 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Tbd"[tiab]. The summary above synthesizes these.
- TBD.
Godellas C · Am J Surg · 2023Editorial
- Tick-Borne Diseases.
Eilbert W, Matella A · Emerg Med Clin North Am · 2024Review
- Treatment of telomeropathies.
Vieri M, Brümmendorf TH, Beier F · Best Pract Res Clin Haematol · 2021Research Support, Non-U.S. Gov't, Review
- Telomere biology disorders.
Kam MLW, Nguyen TTT, Ngeow JYY · NPJ Genom Med · 2021Review
- Frontiers in PROTACs.
Hughes GR, Dudey AP, Hemmings AM, et al. · Drug Discov Today · 2021Review
- Molecular glue CELMoD compounds are regulators of cereblon conformation.
Watson ER, Novick S, Matyskiela ME, et al. · Science · 2022Research Support, N.I.H., Extramural
- Long-term survival, temperature, and torpor patterns.
Geiser F, Ruf T · Sci Rep · 2023Research Support, Non-U.S. Gov't
- [Telomere biology disorder].
Philippot Q, Crestani B, Ba I, et al. · Rev Med Interne · 2026English Abstract, Review
- Clonal landscape and clinical outcomes of telomere biology disorders: somatic rescue and cancer mutations.
Gutierrez-Rodrigues F, Groarke EM, Thongon N, et al. · Blood · 2024
- Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs.
Chamberlain PP, Lopez-Girona A, Miller K, et al. · Nat Struct Mol Biol · 2014Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- TBD-Catalyzed Ring-Opening Polymerization of Alkyl-Substituted Morpholine-2,5-Dione Derivatives.
Dirauf M, Bandelli D, Weber C, et al. · Macromol Rapid Commun · 2018
Other devices of this type
Also filed under product code OOE.
- LENSAR Laser System - fs 3D (LLS-fs 3D)Lensar, Inc. · 510(k) 2018
- VICTUS Femtosecond Laser PlatformTechnolas Perfect Vision GmbH · 510(k) 2020
- LenSx Laser System (8065000944)Alcon Laboratories, Inc. · 510(k) 2025
- Catalys Precision Laser SystemAmo Manufacturing USA, LLC · 510(k) 2023
- Catalys Precision Laser SystemOptimedica Corporation · 510(k) 2016
- Lensx 550 Laser System. Model 550Lensx Lasers, Inc. · 510(k) 2010
- FEMTO LDV Z8 Femtosecond Surgical LaserSie Ag,Surgical Instrument Engineering · 510(k) 2022
- ELITA Femtosecond Laser System, ELITA Patient InterfaceJohnson & Johnson Surgical Vision, Inc. · 510(k) 2023
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.